Down syndrome | Tourette syndrome | Coronary artery bypass surgery | Asperger syndrome | Marfan syndrome | Down Syndrome | Turner syndrome | Down's syndrome | Asperger's syndrome | Acute lymphoblastic leukemia | Williams syndrome | Stockholm syndrome | Severe acute respiratory syndrome | Rett syndrome | Irukandji syndrome | Chronic fatigue syndrome | Wiskott–Aldrich syndrome protein | Tourette Syndrome Association | syndrome | severe acute respiratory syndrome | Premenstrual syndrome | Le syndrome de Peter Pan | Alport syndrome | Acute myeloid leukemia | acute | Usher syndrome | The China Syndrome | Sudden Infant Death Syndrome | Stockholm Syndrome (band) | Stockholm Syndrome |
Varespladib methyl (also known as A-002, formerly LY333013 and S-3013) is a secretory phospholipase A2 (sPLA2) inhibitor formerly under development by Anthera Pharmaceuticals as a treatment for acute coronary syndrome (ACS).